Competitive PressureEvernorth's new benefit option could be a headwind for HIMS, as it offers lower out-of-pocket costs for patients compared to HIMS' partnership pricing.
Pricing StrategyHims is only offering a slight discount at $549/month, compared to the original price of $599/month, for Wegovy, which is less competitive than its rivals.
Regulatory ChallengesAfter May 22nd, compounders can no longer mass produce and sell Semaglutide, potentially impacting HIMS' operations.